重庆医学2012，Vol.41Issue(32)：3372-3374,3.DOI:10.3969/j.issn.1671-8348.2012.32.007
CA125、CA199、CEA联合检测在卵巢癌诊断中的应用
Application of the combined detection of CA125,CA199,CEA on diagnosis of ovarian cancer
摘要
Abstract
Objective To evaluate the clinical value of the combined detection of serum CA125 ,CA199 ,CEA on diagnosis of o-varian cancer. Methods Chemiluminescent microparticle immunoassay (CMIA) was used to detect the serum levels of CA125, CA199,CEA in 72 patients with ovarian cancer,51 patients with benign gynecologic diseases and 60 healthy women. Results The levels and positive rates of CA125 ,CA199 ,CEA in patients with ovarian cancer were significantly higher than those in healthy controls (P<0. 05) ;The levels and positive rates of CA125 ,CA199 in patients with ovarian cancer were obviously higher than those in patients with benign gynecologic diseases(P<0. 05) ;The positive rate of CA125(75%) was the highest among that of three tumor markers; The sensitivity, specificity, positive and negative predictive value of combined detection of CA125, CA199 , CEA was 88. 89%,88. 29%, 83. 12% and 92. 45% .respectively; Compared with CA125 alone,the specificity of combined detection decreased slightly,while other indicators were higher than those of CA125 detection;The positive rates of CA125 for ovarian cancer patients in stage Ⅰ and Ⅱ (stage Ⅰ :27. 27%, stage Ⅱ :46. 67%) were obviously lower than those in stage Ⅲ and Ⅳ (stage Ⅲ :94. 12%, stage Ⅳ :100%). The combined detection of CA125 ,CA199 ,CEA greatly improved the positive rates for patients in stage Ⅰ and Ⅱ (stage Ⅰ :63. 64% ,stage Ⅱ:80%). Conclusion The combined detection of CA125 ,CA199 ,CEA is an ideal marker on diagnosis of ovarian cancer.关键词
卵巢肿瘤/CA125/CA199/CEA/联合检测Key words
ovarian neoplasms/CA125 /CA199 /CEA/combined detection引用本文复制引用
易琳,黄学梅,刘预,李雨聪,林一民,周琦..CA125、CA199、CEA联合检测在卵巢癌诊断中的应用[J].重庆医学,2012,41(32):3372-3374,3.基金项目
国家自然科学基金资助项目(81071812/H1609). （81071812/H1609）
